loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

ERIS Lifesciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Eris Lifesciences Ltd. 29 Jul 2026 13:34 PM

Q1FY27 Quarterly Result Announced for Eris Lifesciences Ltd.

Pharmaceuticals company Eris Lifesciences announced Q1FY27 results

Consolidated Financial Highlights:

  • Total Income for Q1FY27 stood at Rs 875.64 crore, reflecting a YoY growth of 12.88% from Rs 775.69 crore in Q1FY26 and a QoQ growth of 15.40% from Rs 758.79 crore in Q4FY26.
  • Total Revenue from Operations reached Rs 873.25 crore in Q1FY27, representing an increase of 12.97% YoY from Rs 773.00 crore in Q1FY26 and an increase of 15.42% QoQ from Rs 756.56 crore in Q4FY26.
  • Net Profit for the Period was Rs 143.32 crore in Q1FY27, showing a YoY growth of 14.56% compared to Rs 125.10 crore in Q1FY26. However, it experienced a QoQ decline of 48.65% from Rs 279.10 crore in Q4FY26 (noting that Q4FY26 included a significant deferred tax credit).
  • Profit Before Tax (PBT) for Q1FY27 was Rs 179.49 crore, up 11.42% YoY from Rs 161.10 crore in Q1FY26 and up 12.60% QoQ from Rs 159.41 crore in Q4FY26.
  • Total Comprehensive Income for the period stood at Rs 143.38 crore in Q1FY27, compared to Rs 124.53 crore in Q1FY26 and Rs 279.54 crore in Q4FY26.
  • Basic Earnings Per Share (EPS) for Q1FY27 was Rs 10.28, compared to Rs 8.66 in Q1FY26 and Rs 20.60 in Q4FY26.

Standalone Financial Highlights:

  • Total Income for Q1FY27 was Rs 470.37 crore, marking a YoY decline of 21.78% from Rs 601.32 crore in Q1FY26, but a QoQ increase of 54.58% from Rs 304.28 crore in Q4FY26.
  • Total Revenue from Operations stood at Rs 443.99 crore in Q1FY27, a YoY decrease of 23.27% from Rs 578.64 crore in Q1FY26 and a QoQ increase of 60.11% from Rs 277.31 crore in Q4FY26.
  • Net Profit for the Period reached Rs 48.30 crore in Q1FY27, a YoY decline of 51.69% compared to Rs 99.99 crore in Q1FY26. On a sequential basis, the company reported a turnaround from a net loss of Rs 8.60 crore in Q4FY26.
  • Profit Before Tax was Rs 64.14 crore in Q1FY27, compared to Rs 156.26 crore in Q1FY26 and a loss of Rs 32.77 crore in Q4FY26.

Business Highlights:

  • Dividend: The Board of Directors declared an interim dividend of Rs 7.21/- (721%) per equity share of face value Rs 1/- each for the financial year 2026-27 during its meeting held on May 20, 2026.
  • Business Acquisition: During the year ended March 31, 2026 (FY26), the company completed the acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for Rs 50 crore on a slump sale basis.
  • Corporate Restructuring: A Composite Scheme of Arrangement is in progress involving Eris Therapeutics Limited (ETL), Eris Oaknet Healthcare Private Limited, and Aprica Healthcare Limited to merge their domestic businesses into ETL. 
  • Labour Code Impact: The company assessed the impact of the New Labour Codes in FY26, resulting in an incremental expense of Rs 17.24 crore (Consolidated) and Rs 14.67 crore (Standalone) due to changes in the definition of "wages" for gratuity and leave liability.
  • Tax Remeasurement: During FY26, the company remeasured its deferred tax assets and liabilities based on revised tax rates, resulting in a deferred tax credit of Rs 150 crore recognized in the statement of profit and loss.
  • Equity Allotment: The company issued and allotted 35,602 ordinary shares of Rs 1 each under the Employee Stock Option Scheme 2021 during Q1FY27.

Result PDF

Pharmaceuticals company Eris Lifesciences announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 756.56 crore compared to Rs 705.30 crore in Q4FY25 (YoY growth of ~7.3%).
    • FY26: Rs 3,129.42 crore compared to Rs 2,893.64 crore in FY25 (YoY growth of ~8.1%).
  • Net Profit for the period:
    • Q4FY26: Rs 279.10 crore compared to Rs 102.35 crore in Q4FY25 (YoY growth of ~172.7%).
    • FY26: Rs 647.51 crore compared to Rs 374.67 crore in FY25 (YoY growth of ~72.8%).

Standalone Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 277.31 crore compared to Rs 404.77 crore in Q4FY25 (YoY decline of ~31.5%).
    • FY26: Rs 1,821.74 crore compared to Rs 1,697.75 crore in FY25 (YoY growth of ~7.3%).
  • Net Profit for the period:
    • Q4FY26: Net loss of Rs 8.60 crore compared to profit of Rs 30.47 crore in Q4FY25.
    • FY26: Rs 244.05 crore compared to Rs 77.39 crore in FY25 (YoY growth of ~215.3%).

Business Highlights:

  • Dividend Declaration: The Board declared an interim dividend of Rs 7.21 per fully paid-up equity share (at the rate of 721%) for the financial year 2026-2027. The record date is May 29, 2026, and payment will be made on or before June 19, 2026.
  • Acquisitions:
    • Swiss Parenteral Limited (SPL): Completed the acquisition of the remaining minority shares on January 16, 2026, making it a wholly-owned subsidiary.
    • Branded Probiotics Business: Completed the acquisition from Velbiom Probiotics Private Limited on March 31, 2026, for a consideration of Rs 50 crore on a slump sale basis.
  • Regulatory/Tax Impact: Due to eligibility for the concessional tax regime from the financial year 2026-27, the Company remeasured deferred tax assets and liabilities, resulting in a deferred tax credit of Rs 150 crore (consolidated) and Rs 18 crore (standalone) recognized in the Statement of Profit and Loss.
  • Exceptional Items: The Company recorded an exceptional item charge of Rs 17.24 crore (consolidated) and Rs 14.67 crore (standalone) in FY26 related to an increase in gratuity and leave liability due to the implementation of the New Labour Codes.
  • Scheme of Arrangement: The Board approved a composite scheme of arrangement to vest the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) into Eris Therapeutics Limited (ETL) and the amalgamation of Aprica Healthcare Limited (AHL) with ETL. This is subject to necessary statutory approvals.

Result PDF

Pharmaceuticals company Eris Lifesciences announced Q3FY26 results

  • Revenue from operations: Rs 807.45 crore against Rs 727.45 crore during Q3FY25, change 11%.
  • PBT: Rs 145.35 crore against Rs 116.36 crore during Q3FY25, change 25%.
  • PAT: Rs 108.83 crore against Rs 87.06 crore during Q3FY25, change 25%.
  • EPS: Rs 7.32 for Q3FY26.
  • Q3 Capex Rs 78 crore – largely towards Insulin/ GLP-1 and General Injectables
  • Book Tax Rate – 22.5% in Q3
  • OCF-to-EBIDTA ratio: 50% in Q3-26 vs 120% in Q3-25

Result PDF

Pharmaceuticals company Eris Lifesciences announced Q1FY26 results

  • Q1 Revenue: Rs 773 crore, change of 7.4%.
  • Started ramping down Trade Gx business - Revenue down to Rs 3 crore in Q1FY26 vs Rs 13 crore in Q1FY25 - leading to an EBIDTA loss of Rs 5 crore in Q1 (excluding DBF).
  • Q1 EBIDTA: Rs 277 crore - margin expansion of 106 bps YoY from 34.7% to 35.8%, change 11% YoY.
  • 20% YoY reduction in interest expense, from Rs 60 crore in Q1FY25 to Rs 49 crore in Q1FY26.
  • Q1 PAT: Rs 125 crore, change 41% YoY, thereby kickstarting the 3-year cycle of EPS acceleration as per our guidance.

Result PDF

Pharmaceuticals company Eris Lifesciences announced Q3FY25 results

  • Q3FY25 consolidated operating revenue up by 50% to Rs 727 crore.
  • Q3FY25 Margin and Fixed Cost Synergies.
    • Gross Margin down by 604 bps due to significant changes in product/ business mix.
    • Fixed Expenses (% of Revenue) down 436 bps YoY.
  • Q3FY25 EBIDTA Rs 250 crore - YoY growth of 43%.
  • Amortisation and Finance costs reflect the full impact of all acquisitions made till date.
  • Book Tax Rate - 25.2% in Q3FY25.
  • OCF-to-EBIDTA ratio - 120% in Q3FY25.

Result PDF

Pharmaceuticals company Eris Lifesciences announced H1FY25 & Q2FY25 results

  • Q2FY25 consolidated operating revenue up by 47% to Rs 741 crore and H1 up by 50% to Rs 1,461 crore.
  • Q2FY25 Margin and Fixed Cost Synergies.
  • Gross Margin down by 641 bps due to significant changes in product/ business mix.
  • Fixed Expenses (% of Revenue) down 625 bps YoY.
  • EBIDTA Margin (35.7%) in-line with Q2FY24 on account of fixed cost synergies coming in.
  • Q2 EBIDTA Rs 265 crore - YoY growth of 46%.
  • H1 EBIDTA Rs 515 crore - YoY growth of 47%.
  • Amortisation and Finance costs reflect the full impact of all acquisitions made till date.
  • Q2 book tax rate - 25% of PBT; cash tax rate 22%.
  • OCF-to-EBIDTA ratio is 119% in Q2 and 94% in H1.
  • Cash EPS - Rs 20 in H1FY25, same as in H1FY24.

Result PDF

Pharmaceuticals firm Eris Lifesciences announced Q4FY23 & FY23 results:

  • Organic standalone revenue growth - 11.5% (Q4), 9.5% (FY23) & 15.6% (FY23)
  • Consolidated Revenue growth at Rs 4,028 million - 32% (Q4), 25% (FY23), and 31% (FY23)
  • Top-20 Eris mother brands accounting for 70% of revenue grew organically by 17% in FY23
  • Eris MJ (Insulin Business) organically clocks Rs 17 crore revenue in first year of commercial operations
  • Achieved organic growth of 22% in Oaknet base business after 3 flat years during FY20-FY22; full year FY23 Revenue Rs 250 crore (28% growth) with EBIDTA Rs 61 crore (margin 24.4%)
  • Amortisation of Glenmark & DRL brands has been charged for 6 months of FY23 as per statutory requirements; however financial upside from the deals has been minimal during FY23 since the deals were consummated in Q4FY23

 

 

 

Result PDF

Pharmaceuticals firm Eris Lifesciences Announced Q1FY23 Result :

  • Zomelis Mother Brand hits a revenue run rate of Rs. 100 cr. p.a. in just 2.5 years of acquisition, representing a growth of more than 8x in monthly sales since acquisition
  • Glimisave MV crosses a MAT revenue of Rs. 100 cr.; we expect to have a total of four Rs. 100 crore brands by the end of FY23 including Zomelis, Glimisave M, Glimisave MV and Renerve Plus
  • Oaknet business is off to a strong start in Q1 FY23
    • Total Revenue = Rs. 55 crore; Post-deal revenue for Eris = INR 31.5 cr
    • Total EBIDTA = Rs. 10 crore in Q1; this run-rate looks sustainable through the year
  • Executed an in-licensing agreement with Biocon for Glargine – expecting launch in Q3 FY23
  • Expecting stronger momentum in core cardio-metabolic business in subsequent quarters
    • Sharp revival of the market in Jun-July 2022 (13% growth)
    • After a 12-month period of slowdown (4% growth) from Jun-21 to May-22
  • Successfully executing on strategic objective of therapy diversification with 3 emerging therapies (Dermatology, CNS and Women’s Health) collectively accounting for 20% of Branded Formulations revenue and growing at > 25% p.a.
  • FY 23 guidance (including Oaknet)
    • Consolidated Revenue growth of 30%
    • Consolidated EBIDTA growth of 16-17%

 

Result PDF

 Pharmaceuticals company Eris Lifesciences declares Q3FY22 result:

  • Grew by 16.5% YTD in our core Cardio-Metabolic segment despite unprecedented market headwinds in Q2 and Q3 the cardiometabolic market growth hit all-time lows of 4.9% in Q2 and 3.3% in Q3, despite a 4-year median growth rate of 11.2% per quarter
  • Improvement of 128 bps in consolidated 9M EBIDTA margin and 57 bps in 9M PAT margin due to higher MR productivity
  • Growth in standalone YPM to Rs. 5.1 lakh (9M of FY22) compared to Rs. 4.6 lakh (9M of FY21)
  • Operating Cashflow @ 73% of EBIDTA for 9M FY22; Guwahati operations accounted for 81% of revenue in 9M FY22
  • Standalone debtor days of 41 at the end of Q3 FY22
  • Tracking to deliver an EPS growth of 14-15% in FY22, on the back of a 21% EPS growth delivered in FY21

 

Result PDF

FINANCIAL HIGHLIGHTS

  • Favourable product mix resulting in 192 bps increase in standalone gross margin and 294 bps in standalone EBITDA margin (42.5%) in Q2 FY22
  • Standalone debtor days = 39 at the end of Q2 FY22
  • Consol. Net Profit Margin at 32.9% in Q2 FY22
  • Standalone YPM grew from INR 4.60 lacs in H1 FY21 to INR 5.13 lacs in H1 FY22; a yoy growth of 11%
  • Consol. other expenses grew 14.7% yoy in H1 FY22 led by a gradual normalisation of field activities
  • Consol. Net Profit margin stable at 31.7% yoy for H1 FY22

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app